A practical reference on visceral fat: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-19 and is reviewed periodically as new material appears.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Located on pituitary somatotroph cells |
| Signaling route | cAMP–protein kinase A | Gs-coupled receptor pathway |
| Downstream markers | Growth hormone and IGF-1 | Used as pharmacodynamic readouts |
| Common detection | LC-MS/MS | Separates intact peptide from fragments |
| Typical storage | 2–8 °C, protected from light | Applies to solid form before reconstitution |
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
Lyophilized material is typically held under refrigeration between two and eight degrees Celsius, shielded from light and ambient moisture. Peptides of this size adsorb to glass and plastic, so working procedures often call for low-binding containers and as few transfers as possible. Absorbed water during weighing shifts the apparent mass of a sample, and controlling room humidity reduces that source of error. Once dissolved, solutions are kept cold and used within the interval printed on the accompanying label or certificate. Degradation accelerates markedly in dilute aqueous form.
Identity and purity are judged through a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact peptide from truncated, oxidized, and deamidated variants, and the resulting peak-area percentages yield a purity figure. Electrospray ionization mass spectrometry confirms the expected molecular mass and can expose unanticipated modifications. Amino acid analysis and peptide mapping support sequence fidelity, while water content, pH, sterility, and bacterial endotoxin testing describe the physical and microbiological attributes of a finished lot.
=== Pyrethroids === Pyrethroid insecticides mimic the insecticidal activity of the natural compound pyrethrin, the biopesticide found in Pyrethrum (Now Chrysanthemum and Tanacetum) species. They have been modified to increase their stability in the environment. These compounds are nonpersistent sodium channel modulators and are less toxic than organophosphates and carbamates. Compounds in this group are often applied against household pests. Some synthetic pyrethroids are toxic to the nervous system.
=== 2010 census === As of the census of 2010, there were 15,792 people, 6,433 households, and 4,049 families living in the city. The population density was 1,014.9 inhabitants per square mile (391.9/km2). There were 7,057 housing units at an average density of 453.5 per square mile (175.1/km2). The racial makeup of the city was 96.1% White, 0.5% African American, 0.2% Native American, 0.6% Asian, 1.1% from other races, and 1.5% from two or more races. Hispanic or Latino of any race were 3.1% of the population. There were 6,433 households, of which 32.6% had children under the age of 18 living with them, 46.0% were married couples living together, 11.8% had a female householder with no husband present, 5.2% had a male householder with no wife present, and 37.1% were non-families. 30.9% of all households were made up of individuals, and 11.8% had someone living alone who was 65 years of age or older. The average household size was 2.38 and the average family size was 2.97. The median age in the city was 37.5 years. 24.5% of residents were under the age of 18; 8.5% were between the ages of 18 and 24; 26.8% were from 25 to 44; 25.6% were from 45 to 64; and 14.7% were 65 years of age or older. The gender makeup of the city was 48.0% male and 52.0% female.
=== Genetic variations === An epigenetic mechanism (hypermethylation of CpG islands in the NET gene promoter region) that results in reduced expression of the noradrenaline (norepinephrine) transporter and consequently a phenotype of impaired neuronal reuptake of norepinephrine has been implicated in both postural orthostatic tachycardia syndrome and panic disorder. rs5569 is a variant of SLC6A2.
The modifications covered in this diagram have to do with stereochemistry and the assignment of unique Cahn-Ingold-Prelog R/S assignments to complex analogues of fentanyl. The stereochemistry of fentanyl analogues can seem at first counter-intuitive, because of the complex and unique nature of the reasoning organic chemists must develop to internalize complex three dimensional geometries such as those needed to comprehend stereochemistry. Thankfully these images follow a simple procedure for organizing a potential analogue of fentanyl into the total number of unique stereoisomers, the number of true stereocenters on the molecule, and the number of Cahn-Ingold-Prelog R/S assignments that are appropriate for that analogue. The procedure used in the analysis of stereochemistry in these series of images is the following:
Additionally, defects in both GSY1 and the SCNA4 gene, responsible for hyperkalemic periodic paralysis (HYPP) in Quarter Horses and related breeds, has been found in 14% of Halter horses. A combination of both of these genes can cause severe rhabdomyolysis should the horse become recumbent due to an HYPP attack.
Sources: en.wikipedia.org
==== 800–899 ==== South Eastern Combined Fire Area Administration (Amendment) (No. 2) Scheme Order 1993 (S.I. 1993/800) Greater London and Kent (County Boundaries) (Variation) Order 1993 (S.I. 1993/805) Pensions Increase (Civil Service Early Retirement Pension Scheme 1992) Regulations 1993 (S.I. 1993/806) Injuries in War (Shore Employments) Compensation (Amendment) Scheme 1992 S.I. 1993/807) Devon Ambulance Service National Health Service Trust Dissolution Order 1993 (S.I. 1993/809) Cornwall Community Healthcare National Health Service Trust Dissolution Order 1993 (S.I. 1993/810) Walsgrave Hospitals National Health Service Trust (Establishment) Order 1993 (S.I. 1993/811) Walsgrave Hospital National Health Service Trust Dissolution Order 1993 (S.I. 1993/812) Cornwall Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/813) Westcountry Ambulance Services National Health Service Trust (Establishment) Order 1993 (S.I. 1993/814) Reconstitution of the Romney Marsh Levels Internal Drainage Board Order 1993 (S.I. 1993/815) Reconstitution of the Finningley Internal Drainage Board Order 1993 (S.I. 1993/816) Reconstitution of the River Stour (Kent) Internal Drainage Board S.I. 1993/817) Civil Legal Aid (Scotland) Amendment (No.2) Regulations 1993 (S.I. 1993/818) Advice and Assistance (Scotland) Amendment (No.2) Regulations 1993 (S.I. 1993/819) Harefield Hospital National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/820) Social Security (Contributions) Amendment (No. 5) Regulations 1993 (S.I.
=== Chemical flocculant === Potassium alum has been used since remote antiquity for purification of turbid liquids. It is still widely used in the purification of water for drinking and industrial processes water, treatment of effluents and post-storm treatment of lakes to precipitate contaminants. Between 30 and 40 ppm of alum for household wastewater, often more for industrial wastewater, is added to the water so that the negatively charged colloidal particles clump together into "flocs", which then float to the top of the liquid, settle to the bottom of the liquid, or can be more easily filtered from the liquid, prior to further filtration and disinfection of the water. Like other similar salts, it works by neutralizing the electrical double layer surrounding very fine suspended particles, allowing them to join into flocs. The same principle is exploited when using alum to increase the viscosity of a ceramic glaze suspension; this makes the glaze more readily adherent and slows its rate of sedimentation.
==== Elimination ==== Mescaline given orally is excreted 87% in urine within 24 hours and 92% in urine within 48 hours. During the first hour after administration, 81.4% of mescaline is excreted unchanged while 13.2% is excreted as its deaminated metabolite 3,4,5-trimethoxyphenylacetic acid (TMPAA). However, after the first hour, the percentage excreted as unchanged mescaline declines and the percentage excreted as TMPAA rises. Ultimately, mescaline is excreted in urine 28 to 60% unchanged, 27 to 30% or more as TMPAA, 5% as N-acetyl-3,4-dimethoxy-5-hydroxyphenylethylamine, and less than 0.1% as N-acetylmescaline. Other minor or trace excreted metabolites have also been observed. In a more modern study published in 2025, mescaline was eliminated in urine 53% as unchanged mescaline and 31% as TMPAA. Mescaline was originally reported to have an elimination half-life of 6 hours based on a study conducted in the 1960s. However, subsequent research published in the 2020s found that its half-life is actually about 3.6 hours (range 2.6–5.3 hours). The previous higher estimate is believed to have been due to small sample numbers and collective measurement of mescaline metabolites. The elimination half-life of mescaline does not appear to be dose-dependent. TMPAA has a half-life of about 3.7 to 4.1 hours, similar to that of mescaline. Mescaline has a similar half-life as LSD yet has a longer duration. This is due to mescaline having slower absorption and onset rather than a longer half-life.
=== Apodization in imaging === Since side lobes of the Airy disk are responsible for degrading the image, techniques for suppressing them are used. If the imaging beam has a Gaussian distribution, then when the truncation ratio (the ratio of the diameter of the Gaussian beam to the diameter of the truncating aperture) is set to 1, the side-lobes become negligible and the beam profile becomes purely Gaussian. In medical ultrasonography, the effect of grating lobes can be reduced by activating ultrasonic transducer elements using variable voltages in the apodization process.
=== Over the counter === In 1998, in an unprecedented action in the United States, an American insurance company, Anthem Inc., petitioned the federal Food and Drug Administration to allow loratadine and two other antihistamines to be made available over the counter (OTC) while they were still protected by patents; the administration granted the request, which was not binding on manufacturers. In the United States, Schering-Plough made loratadine available over the counter in 2002. By 2015, loratadine was available over the counter in many countries.
Sources: en.wikipedia.org
Although cadmium usually has an oxidation state of +2, it also exists in the +1 state. Cadmium and its congeners are not always considered transition metals, in that they do not have partly filled d or f electron shells in the elemental or common oxidation states. Cadmium burns in air to form brown amorphous cadmium oxide (CdO); the crystalline form of this compound is a dark red which changes color when heated, similar to zinc oxide. Hydrochloric acid, sulfuric acid, and nitric acid dissolve cadmium by forming cadmium chloride (CdCl2), cadmium sulfate (CdSO4), and cadmium nitrate (Cd(NO3)2) respectively. The oxidation state +1 can be produced by dissolving cadmium in a mixture of cadmium chloride and aluminium chloride, forming the Cd2+2 cation as cadmium(I) tetrachloroaluminate, which is similar to the Hg2+2 cation in mercury(I) chloride.
=== U.S. relations with Marshall Islands === Section 177 of the 1983 Compact of Free Association between the governments of the United States and the Marshall Islands establishes a process for Marshallese to make a claim against the United States government as a result of damage and injury caused by nuclear testing. That same year, an agreement was signed to implement Section 177, which established a US$150 million trust fund. The fund was intended to generate US$18 million a year, which would be payable to claimants on an agreed-upon schedule. If the US$18 million a year generated by the fund was not enough to cover claims, the principal of the fund could be used. A Marshall Islands Nuclear Claims Tribunal was established to adjudicate claims. In 2000, the tribunal made a compensation award to the people of Enewetak consisting of US$107.8 million for environmental restoration; US$244 million in damages to cover economic losses caused by loss of access and use of the atoll; and US$34 million for hardship and suffering. In addition, as of the end of 2008, another US$96.658 million in individual damage awards were made. Only US$73.526 million of the individual claims award has been paid, however, and no new awards were made between the end of 2008 and May 2010. Due to stock market losses, payments rates that have outstripped fund income, and other issues, the fund was nearly exhausted, as of May 2010, and unable to make any additional awards or payments.
In 1977, Migita published further work on the coupling of allyl-tin reagents with both aryl (C) and acyl (D) halides. The greater ability of allyl groups to migrate to the palladium catalyst allowed the reactions to be performed at lower temperatures. Yields for aryl halides ranged from 4% to 100%, and for acyl halides from 27% to 86%. Reflecting the early contributions of Migita and Kosugi, the Stille reaction is sometimes called the Migita–Kosugi–Stille coupling.
(It should not be supposed that these chains have no branches: the diagram below shows a few branches of chains, and in reality there are many more, because there are many more isotopes possible than are shown in the diagram.) For example, the third atom of nihonium-278 synthesised underwent six alpha decays down to mendelevium-254, followed by an electron capture (a form of beta decay) to fermium-254, and then a seventh alpha to californium-250, upon which it would have followed the 4n + 2 chain (radium series) as given in this article. However, the heaviest superheavy nuclides synthesised do not reach the four decay chains, because they reach a spontaneously fissioning nuclide after a few alpha decays that terminates the chain: this is what happened to the first two atoms of nihonium-278 synthesised, as well as to all heavier nuclides produced. Three of those chains have a long-lived isotope (or nuclide) near the top; this long-lived nuclide is a bottleneck in the process through which the chain flows very slowly, and keeps the chain below them "alive" with flow. The three long-lived nuclides are uranium-238 (half-life 4.463 billion years), uranium-235 (half-life 704 million years) and thorium-232 (half-life 14.1 billion years). The fourth chain has no such long-lasting bottleneck nuclide near the top, so that chain has long since decayed down to the last before the end: bismuth-209.
Sources: en.wikipedia.org
It acts on the growth hormone–releasing hormone receptor, a Gs-coupled receptor found on pituitary somatotroph cells. Activation raises cAMP and prompts pulsatile hormone release.
IGF-1 reflects growth hormone activity but changes slowly and can be measured from one sample. Growth hormone itself is pulsatile, which makes single measurements hard to interpret.
The receptor pathway is well described, but how individual responses vary and what governs long-term outcomes remain open questions. Reported differences across studies are often attributed to assay and population factors.
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.